Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Extends Target-Discovery Deal With Novartis

NEW YORK (GenomeWeb News) — Cellzome has extended until June 2008 its research agreement with Novartis, the company said yesterday.
 
Under the terms of the partnership, Cellzome will continue to use its proteomics and pathway mapping experience to identify therapeutic and pharmacological targets to Novartis compounds.
 
Financial details of the arrangement were not disclosed, but Cellzome said there are “compound development options for both companies in exchange for licenses, milestone payments and royalties.”
 
The companies first entered their agreement in 2004 and renewed it last year. In 2005 Novartis made a “substantial equity investment” in the privately held company, Cellzome said

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.